Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
Authors
Keywords
-
Journal
Diabetes Therapy
Volume 3, Issue 1, Pages -
Publisher
Springer Nature
Online
2012-06-27
DOI
10.1007/s13300-012-0008-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Linagliptin
- (2011) Lesley J. Scott DRUGS
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
- (2010) K. J. Hare et al. DIABETES
- Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
- (2010) D. R. Matthews et al. DIABETES OBESITY & METABOLISM
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
- (2010) C. Filozof et al. DIABETIC MEDICINE
- Sitagliptin
- (2010) Sohita Dhillon DRUGS
- Vildagliptin
- (2010) Gillian M. Keating DRUGS
- The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats
- (2010) Alokesh Duttaroy et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
- (2009) G. Bolli et al. DIABETES OBESITY & METABOLISM
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- (2009) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Saxagliptin
- (2009) Sohita Dhillon et al. DRUGS
- Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
- (2008) Michael Boschmann et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes
- (2007) Koichiro Azuma et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now